| Literature DB >> 33232298 |
Vaibhav Sidarala1, Gemma L Pearson1, Vishal S Parekh2, Benjamin Thompson2, Lisa Christen3, Morgan A Gingerich1,4, Jie Zhu1, Tracy Stromer1, Jianhua Ren2, Emma C Reck1, Biaoxin Chai1, John A Corbett5, Thomas Mandrup-Poulsen3, Leslie S Satin1,2, Scott A Soleimanpour1,6.
Abstract
Inflammatory damage contributes to β cell failure in type 1 and 2 diabetes (T1D and T2D, respectively). Mitochondria are damaged by inflammatory signaling in β cells, resulting in impaired bioenergetics and initiation of proapoptotic machinery. Hence, the identification of protective responses to inflammation could lead to new therapeutic targets. Here, we report that mitophagy serves as a protective response to inflammatory stress in both human and rodent β cells. Utilizing in vivo mitophagy reporters, we observed that diabetogenic proinflammatory cytokines induced mitophagy in response to nitrosative/oxidative mitochondrial damage. Mitophagy-deficient β cells were sensitized to inflammatory stress, leading to the accumulation of fragmented dysfunctional mitochondria, increased β cell death, and hyperglycemia. Overexpression of CLEC16A, a T1D gene and mitophagy regulator whose expression in islets is protective against T1D, ameliorated cytokine-induced human β cell apoptosis. Thus, mitophagy promotes β cell survival and prevents diabetes by countering inflammatory injury. Targeting this pathway has the potential to prevent β cell failure in diabetes and may be beneficial in other inflammatory conditions.Entities:
Keywords: Apoptosis survival pathways; Diabetes; Endocrinology; Mitochondria
Mesh:
Substances:
Year: 2020 PMID: 33232298 PMCID: PMC7819751 DOI: 10.1172/jci.insight.141138
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708